Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow

• DOI: 10.1046/j.1365-2222.2000.00749.x
• Publication Date: 2003-03-11T09:43:17Z
• Authors: Wilson; Dempsey; Sims; Coutie; Paterson; Lipworth
• Keywords: Mometasone furoate; Nasal congestion

Background Measurement of domiciliary nasal peak inspiratory flow rate (PIFR) may have a role in the objective assessment treatment response seasonal allergic rhinitis (SAR). Objective We wished to evaluate relationship between measurement PIFR and variety symptoms associated with rhinitis. Methods Thirty‐eight nonasthmatic patients, mean age (SEM) 30 years (1.4), symptomatic SAR were evaluated placebo‐controlled, single‐blind, double‐dummy, three way parallel group study. Patients received oral cetirizine 10 mg once daily randomized receive, addition, either: (i) intranasal mometasone furoate 200 μg ( n = 14); (ii) montelukast 11); or (iii) placebo 13). All treatments given for 4 weeks preceded by 1 week period. Domiciliary diary cards used record morning (am) evening (pm) symptom (nasal, eye, throat) scores impact on activity. A total score was then calculated from sum these separate scores. Results Baseline values after run‐in not significantly different when comparing groups. After active treatment, there significant P < 0.05) improvements symptoms, all treatments, being no confounding effect pollen count, analysed as covariate. There 0.01) correlations vs PIFRam r − 0.51) PIFRpm 0.56), similarly activity 0.42) 0.48). Conclusions These results suggest that measurements correlate therefore be potentially useful short‐term marker response.